• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓纤维化和原发性血小板增多症向白血病的演变:基因组特征可预测转化时间。

Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.

机构信息

Université d'Angers, Inserm, CRCINA, Angers, France.

Unité de Formation et de Recherche (UFR) Santé, Université d'Angers, Angers, France.

出版信息

Blood Adv. 2020 Oct 13;4(19):4887-4897. doi: 10.1182/bloodadvances.2020002271.

DOI:10.1182/bloodadvances.2020002271
PMID:33035330
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7556129/
Abstract

Among myeloproliferative neoplasms, polycythemia vera (PV) and essential thrombocythemia (ET) are the 2 entities associated with the most chronic disease course. Leukemic evolution occurs rarely but has a grim prognosis. The interval between diagnosis and leukemic evolution is highly variable, from a few years to >20 years. We performed a molecular evaluation of 49 leukemic transformations of PV and ET by targeted next-generation sequencing. Using a hierarchical classification, we identified 3 molecular groups associated with a distinct time to leukemic transformation. Short-term transformations were mostly characterized by a complex molecular landscape and mutations in IDH1/2, RUNX1, and U2AF1 genes, whereas long-term transformations were associated with mutations in TP53, NRAS, and BCORL1 genes. Studying paired samples from chronic phase and transformation, we detected some mutations already present during the chronic phase, either with a significant allele burden (short-term transformation) or with a very low allele burden (especially TP53 mutations). However, other mutations were not detected even 1 year before leukemic transformation. Our results suggest that the leukemic transformation of PV and ET may be driven by distinct time-dependent molecular mechanisms.

摘要

在骨髓增殖性肿瘤中,真性红细胞增多症(PV)和原发性血小板增多症(ET)是与病程最慢性相关的两种疾病。白血病转化虽然罕见,但预后较差。从诊断到白血病转化的间隔时间差异很大,从几年到超过 20 年不等。我们通过靶向下一代测序对 49 例 PV 和 ET 的白血病转化进行了分子评估。通过分层分类,我们确定了 3 个与白血病转化时间明显相关的分子群。短期转化主要表现为复杂的分子谱和 IDH1/2、RUNX1 和 U2AF1 基因突变,而长期转化与 TP53、NRAS 和 BCORL1 基因突变相关。研究慢性期和转化期的配对样本,我们发现了一些在慢性期就已经存在的突变,要么具有显著的等位基因负担(短期转化),要么具有非常低的等位基因负担(尤其是 TP53 突变)。然而,即使在白血病转化前 1 年,也未检测到其他突变。我们的结果表明,PV 和 ET 的白血病转化可能由不同的、随时间变化的分子机制驱动。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2664/7556129/de0bb4f67031/advancesADV2020002271absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2664/7556129/de0bb4f67031/advancesADV2020002271absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2664/7556129/de0bb4f67031/advancesADV2020002271absf1.jpg

相似文献

1
Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.骨髓纤维化和原发性血小板增多症向白血病的演变:基因组特征可预测转化时间。
Blood Adv. 2020 Oct 13;4(19):4887-4897. doi: 10.1182/bloodadvances.2020002271.
2
Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia.与真性红细胞增多症和原发性血小板增多症急变相关的基因损伤。
Genes Chromosomes Cancer. 1997 Aug;19(4):250-5.
3
Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.对JAK2V617F突变的真性红细胞增多症或原发性血小板增多症患者进行长期分子随访中的非驱动突变
Ann Hematol. 2018 Mar;97(3):443-451. doi: 10.1007/s00277-017-3193-5. Epub 2017 Nov 27.
4
Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective.从单细胞角度看骨髓增殖性肿瘤向白血病演变的新分子认识。
Int J Mol Sci. 2022 Dec 3;23(23):15256. doi: 10.3390/ijms232315256.
5
Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia.对大量真性红细胞增多症和原发性血小板增多症患者进行非驱动基因突变分析。
Eur J Haematol. 2023 Feb;110(2):131-136. doi: 10.1111/ejh.13882. Epub 2022 Oct 17.
6
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.真性红细胞增多症和原发性血小板增多症:2015 年诊断、风险分层和治疗更新。
Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895.
7
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.原发性血小板增多症和真性红细胞增多症中的驱动突变(JAK2V617F、MPLW515L/K或CALR)、五聚体蛋白3和C反应蛋白。
J Hematol Oncol. 2017 Feb 22;10(1):54. doi: 10.1186/s13045-017-0425-z.
8
Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.儿童真性红细胞增多症和原发性血小板增多症中骨髓增殖性疾病的标志物。
J Clin Oncol. 2007 Mar 20;25(9):1048-53. doi: 10.1200/JCO.2006.08.6884.
9
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.真性红细胞增多症和原发性血小板增多症:2021 年诊断、风险分层和治疗更新。
Am J Hematol. 2020 Dec;95(12):1599-1613. doi: 10.1002/ajh.26008. Epub 2020 Oct 23.
10
CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.四种不同亚型骨髓增殖性肿瘤患者(原发性骨髓纤维化、原发性血小板增多症、真性红细胞增多症和无法分类的骨髓增殖性肿瘤)的CALR、JAK2和MPL突变谱
Am J Clin Pathol. 2015 May;143(5):635-44. doi: 10.1309/AJCPUAAC16LIWZMM.

引用本文的文献

1
A molecular signature predicts hematologic evolution in polycythemia vera patients.一种分子特征可预测真性红细胞增多症患者的血液学演变。
Leukemia. 2025 Jun 18. doi: 10.1038/s41375-025-02660-0.
2
Polycythaemia vera.真性红细胞增多症
Nat Rev Dis Primers. 2025 Apr 17;11(1):26. doi: 10.1038/s41572-025-00608-3.
3
Contribution of molecular characterization to the diagnosis of MPN in patients with low JAK2 variant allelic fraction in a real-world cohort.分子特征在真实世界队列中对JAK2变异等位基因分数低的骨髓增殖性肿瘤患者诊断中的贡献

本文引用的文献

1
Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?Ph1 阴性骨髓增殖性肿瘤转化后是否仍应考虑移植?
Biol Blood Marrow Transplant. 2020 Jun;26(6):1160-1170. doi: 10.1016/j.bbmt.2020.02.019. Epub 2020 Feb 28.
2
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.突变增强的原发性血小板增多症和真性红细胞增多症国际预后系统。
Br J Haematol. 2020 Apr;189(2):291-302. doi: 10.1111/bjh.16380. Epub 2020 Jan 16.
3
Therapy-associated leukemic transformation in myeloproliferative neoplasms - What do we know?
Ann Hematol. 2025 Mar;104(3):1587-1596. doi: 10.1007/s00277-025-06326-w. Epub 2025 Apr 1.
4
Whole-genome sequencing of myeloproliferative neoplasms revealed dynamic clonal changes in the fibrotic or leukemic transformation and novel FOXP1 mutations in the fibrotic transformation.骨髓增殖性肿瘤的全基因组测序揭示了纤维化或白血病转化过程中的动态克隆变化以及纤维化转化中的新型FOXP1突变。
Leukemia. 2025 May;39(5):1218-1227. doi: 10.1038/s41375-025-02576-9. Epub 2025 Mar 31.
5
Polycythemia vera and essential thrombocythemia in children, still a challenge for pediatricians.儿童真性红细胞增多症和原发性血小板增多症,对儿科医生来说仍是一项挑战。
Eur J Pediatr. 2025 Feb 4;184(2):173. doi: 10.1007/s00431-025-05993-1.
6
Pathogenesis and management of high molecular risk myeloproliferative neoplasms.高危分子骨髓增殖性肿瘤的发病机制与管理
Haematologica. 2025 Apr 1;110(4):863-876. doi: 10.3324/haematol.2023.283987. Epub 2024 Dec 5.
7
Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety.鲁索替尼获批用于真性红细胞增多症十年经验回顾:临床疗效与安全性综述
Cancer. 2025 Jan 1;131(1):e35661. doi: 10.1002/cncr.35661. Epub 2024 Dec 1.
8
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies.老年急性髓系白血病:从新的生物学见解到靶向治疗。
Curr Oncol. 2024 Oct 24;31(11):6632-6658. doi: 10.3390/curroncol31110490.
9
Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia.骨髓增殖性肿瘤转化为急性髓系白血病的防治
Haematologica. 2025 Apr 1;110(4):828-839. doi: 10.3324/haematol.2023.283950. Epub 2024 Oct 24.
10
Transformation into acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1::RUNX1T1 from JAK2-mutated essential thrombocythemia: a case report.从 JAK2 突变型原发性血小板增多症转化为急性髓系白血病伴 t(8;21)(q22;q22.1);RUNX1::RUNX1T1:一例报告。
J Med Case Rep. 2024 Aug 18;18(1):372. doi: 10.1186/s13256-024-04691-0.
治疗相关性髓系肿瘤白血病转化:我们了解多少?
Best Pract Res Clin Haematol. 2019 Mar;32(1):65-73. doi: 10.1016/j.beha.2019.02.004. Epub 2019 Feb 8.
4
RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs.RUNX1 突变增强了人类体外模型和原发性 AML 中的自我更新并阻断了粒细胞分化。
Blood Adv. 2019 Feb 12;3(3):320-332. doi: 10.1182/bloodadvances.2018024422.
5
Positive impact of molecular analysis on prognostic scores in essential thrombocythemia: a single center prospective cohort experience.分子分析对原发性血小板增多症预后评分的积极影响:一项单中心前瞻性队列研究经验
Haematologica. 2019 Apr;104(4):e134-e137. doi: 10.3324/haematol.2018.197699. Epub 2018 Oct 18.
6
The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.加速期和急变期骨髓增殖性肿瘤的突变特征影响患者结局。
Blood Adv. 2018 Oct 23;2(20):2658-2671. doi: 10.1182/bloodadvances.2018021469.
7
Classification and Personalized Prognosis in Myeloproliferative Neoplasms.骨髓增殖性肿瘤的分类与个体化预后
N Engl J Med. 2018 Oct 11;379(15):1416-1430. doi: 10.1056/NEJMoa1716614.
8
Comprehensive Characterization of Cancer Driver Genes and Mutations.全面描绘癌症驱动基因和突变。
Cell. 2018 Apr 5;173(2):371-385.e18. doi: 10.1016/j.cell.2018.02.060.
9
Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase.阴性骨髓增殖性肿瘤转化为加速期或白血病期的转归
Leuk Lymphoma. 2018 Dec;59(12):2812-2820. doi: 10.1080/10428194.2018.1441408. Epub 2018 Apr 4.
10
Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.靶向二代测序在骨髓增殖性肿瘤中 blast 期的应用。
Blood Adv. 2018 Feb 27;2(4):370-380. doi: 10.1182/bloodadvances.2018015875.